GSK1324726A (I-BET726)
|
|
- CAS-Nr.
- 1300031-52-0
- Englisch Name:
- GSK1324726A (I-BET726)
- Synonyma:
- GSK1324726A;CS-1736;I-BET726;I-BET726; I-BET 726;GSK1324726A (I-BET726);I-BET726 (GSK1324726A);GSK1324726A (I-BET726) USP/EP/BP;GSK-1324726A,Apoptosis,GSK1324726A,Inhibitor,Epigenetic Reader Domain,inhibit;4-(cis-1-Acetyl-4-((4-chlorophenyl)amino)-2-methyl-1,2,3,4-tetrahydroquinolin-6-yl)benzoic acid;4-((2S,4R)-1-acetyl-4-(4-chlorophenylamino)-2-methyl-1,2,3,4-tetrahydroquinolin-6-yl)benzoic acid
- CBNumber:
- CB62677051
- Summenformel:
- C25H23ClN2O3
- Molgewicht:
- 434.91
- MOL-Datei:
- 1300031-52-0.mol
|
GSK1324726A (I-BET726) Eigenschaften
- Siedepunkt:
- 707.3±60.0 °C(Predicted)
- Dichte
- 1.304±0.06 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- L?slichkeit
- insoluble in H2O; ≥1.87 mg/mL in EtOH with gentle warming and ultrasonic; ≥17.7 mg/mL in DMSO
- Aggregatzustand
- Powder
- pka
- 4.20±0.10(Predicted)
- Farbe
- White to light yellow
- InChIKey
- FAWSUKOIROHXAP-NPMXOYFQSA-N
- SMILES
- C(O)(=O)C1=CC=C(C2C=CC3=C(C=2)[C@H](NC2=CC=C(Cl)C=C2)C[C@H](C)N3C(C)=O)C=C1
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
Bildanzeige (GHS) |
|
Alarmwort |
Warnung |
Gefahrenhinweise |
Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
H302 |
Gesundheitssch?dlich bei Verschlucken. |
Akute Toxizit?t oral |
Kategorie 4 |
Warnung |
src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
|
Sicherheit |
P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen. |
|
GSK1324726A (I-BET726) Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
I-BET726 is an inhibitor of BET family proteins that binds BRD2, BRD3, and BRD4 with high affinity (IC
50s = 41, 31, and 22 nM, respectively) and competes with tetra-acetylated histone 4 peptides for binding to the bromodomains of these proteins. It exhibits >1,000-fold selectivity for these proteins over other bromodomain-containing homologs. I-BET726 inhibits cell growth and induces cytotoxicity in neuroblastoma cell lines by modulating the expression of genes involved in apoptosis and Myc signaling. I-BET726 can be administered orally to animals, and it reduces tumor growth in mouse xenograft models of human neuroblastoma.
GSK1324726A (I-BET726) Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
GSK1324726A (I-BET726) Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 71)Lieferanten
- 4-((2S,4R)-1-acetyl-4-(4-chlorophenylamino)-2-methyl-1,2,3,4-tetrahydroquinolin-6-yl)benzoic acid
- 4-[(2S,4R)-1-Acetyl-4-[(4-chlorophenyl)amino]-2-methyl-1,2,3,4-tetrahydro-6-quinolinyl]benzoic acid
- GSK1324726A (I-BET726)
- 4-(cis-1-Acetyl-4-((4-chlorophenyl)amino)-2-methyl-1,2,3,4-tetrahydroquinolin-6-yl)benzoic acid
- I-BET726; I-BET 726
- CS-1736
- 4-[(2S,4R)-1-Acetyl-4-[(4-chlorophenyl)amino]-1,2,3,4-tetrahydro-2-methyl-6-quinolinyl]benzoic acid
- I-BET726
- Benzoic acid, 4-[(2S,4R)-1-acetyl-4-[(4-chlorophenyl)amino]-1,2,3,4-tetrahydro-2-methyl-6-quinolinyl]-
- GSK1324726A (I-BET726) USP/EP/BP
- GSK1324726A
- GSK-1324726A,Apoptosis,GSK1324726A,Inhibitor,Epigenetic Reader Domain,inhibit
- I-BET726 (GSK1324726A)
- 1300031-52-0
- Inhibitors